Immodulon Therapeutics Competitors and Similar CompaniesClear all
Immodulon Therapeutics's competitors and similar companies include Omeros, Halozyme Therapeutics, HUYA Bioscience International and Annam Biosciences.
 Immodulon Therapeutics Immodulon Therapeutics is an immuno-oncology company focused on the development of treatments for cancer. |  Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  HUYA Bioscience International HUYA Bioscience International is a company specializing in the biopharmaceutical products. | ||
Founding Date | Founding Date N/A | Founding Date 1994 | Founding Date 1998 | Founding Date 2004 | Founding Date 2012 |
Type | Type Private | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Hayes, GB HQ London, GB | Locations Seattle, US HQ | Locations San Diego, US HQ | Locations San Diego, US HQ Chengdu Shi, CN Guangzhou Shi, CN Hangzhou, CN Shenzhen Shi, CN Shenzhen Shi, CN Suzhou Shi, CN see more | Locations San Diego, US HQ |
Employees | Employees 10 | Employees 1968% decrease | Employees 373157% increase | Employees 1113% increase | Employees 2 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 248.6 m | Valuation ($) 6.4 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Net income | Net income N/A | Net income ($3.4m) (FY, 2025) | Net income $316.9m (FY, 2025) | Net income N/A | Net income N/A |
Operating ⚠ | |||||
Patents (US) | Patents (US) N/A | Patents (US) 80 (FY, 2021) | Patents (US) 43 (FY, 2020) | Patents (US) N/A | Patents (US) N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 3 (FY, 2021) | Phase I Trials Products 10 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 2 (FY, 2021) | Phase II Trials Products 1 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 2 (FY, 2021) | Phase III Trials Products 8 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Preclinical Phase Products | Preclinical Phase Products N/A | Preclinical Phase Products 5 (FY, 2021) | Preclinical Phase Products 2 (FY, 2018) | Preclinical Phase Products N/A | Preclinical Phase Products N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 354.8m | Total funding raised $ 171.9m | Total funding raised $ 12.6m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Omeros
HQ
Seattle, US
Employees
196↓ 8% decrease
Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers.
View companyHalozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyHUYA Bioscience International
HQ
San Diego, US
Employees
111↑ 3% increase
HUYA Bioscience International is a company specializing in the biopharmaceutical products.
View company
Annam Biosciences
HQ
San Diego, US
Employees
2
Annam is an early-stage biotech company that focuses on oncology products.
View company